Evercore ISI lowered the firm’s price target on Bio-Techne (TECH) to $68 from $72 and keeps an Outperform rating on the shares. The firm said it is trimming expectations for organic growth due to timing issue with cell therapy customers, yet the macro recovery thesis remains intact.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target raised to $70 from $65 at UBS
- Bio-Techne price target lowered to $61 from $62 at Baird
- Bio-Techne Reports Q1 FY2026 Earnings with Strategic Focus
- Bio-Techne’s Earnings Call: Mixed Sentiment Amid Growth and Challenges
- Positive Long-Term Outlook for Bio-Techne Amid Short-Term Challenges